Wikipedia
WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.
Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.
advertisement
Pharmaceutical groups and patient advocates are increasingly fighting that approach.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Merck to buy EyeBio, maker of eye drug, as it grows pipeline
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
